Does CBT pay a dividend and is it safe?

Cabot Corporation (CBT) offers a 2.52% cash dividend yield ($1.91 annualized) and 4.32% total shareholder yield including buybacks. Roarable rates its payout coverage as FORTRESS PAYOUT.

Stock Ratings / Materials / CBT / dividends

AVNT (69) VVV (45) PRM (43) WDFC (73) ⌘ Pro Terminal →

Cabot Corporation (CBT) Dividend Safety Gauge & 10-Year DRIP Compounder

$75.72 +1.73% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $75.81

Cabot Corporation (CBT) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $3.84B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CBT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cabot Corporation (NYSE: CBT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $75.72 (+1.73% 1D, market cap $3.84B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 18/20. Across 270 tracked Materials issuers, CBT ranks #20 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CBT compare to AVNT and VVV in the Materials sector?

▼

Within the Materials sector (Major Chemicals), CBT carries a Roarable C (65/100 RQD), trailing P/E of 11.5x, gross margin of 25.3%, and ROIC of 22.3%. By comparison, AVNT (Avient Corporation) holds a C+ grade (69/100 RQD, P/E 48.0x, ROIC 3.7%, cap $3.93B) and VVV (Valvoline Inc.) posts a D grade (45/100 RQD, P/E 19.6x, ROIC 16.5%, cap $4.12B). Among the 5-stock peer group, CBT leads on earnings multiple (11.5x) while WDFC leads on capital efficiency (27.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CBT?

▼

Per CBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000016040), Cabot Corporation generated $3.71B in revenue (-7.0% YoY), $331.0M in net income, and $391.0M in free cash flow against $3.76B in total assets and $854.0M in total debt. Key quantitative strengths: Strong cash generator (25.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $75.81 (+0.12%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 10.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CBT)Realized 20D OHLCV Swing Band: ±4%

Deterministic 5-Pillar Attribution (65/100 Composite)

🔍 WHY CBT SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 10.5% FCF Margin ($391.0M FCF) & 25.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$75.47-2.5% Next Q

Q2 (-2Q)

Grade C$73.62+0.5% Next Q

Q3 (-1Q)

Grade C+$74.02+2.3% Next Q

Current

Grade C$75.72+1.3% Hist 90D α

Trajectory: C (57) → C (65)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CBT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, CBT faces multiple-compression risk if 11.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 22.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($77.54) or 200D SMA ($79.56) invalidates the momentum regime and cuts Target Base ($78.11) toward Bear Floor ($60.93).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CBT Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 65%NO 35%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

4.32% Total Yield

2.52% Cash ($1.91/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

88/100 • FORTRESS PAYOUT

FREE CASH FLOW PAYOUT RATIO

16% of FCF

8 consecutive years of payout growth

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (7.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $21,193

Est. Year-10 Shareholder Yield: $916/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.8K

Yr 1

$11.6K

Yr 2

$12.5K

Yr 3

$13.5K

Yr 4

$14.6K

Yr 5

$15.7K

Yr 6

$16.9K

Yr 7

$18.2K

Yr 8

$19.7K

Yr 9

$21.2K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in CBT & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on CBT and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.17%📐 HORIZONTAL RANGE

2026-11-03O $73.85H $75.72L $73.85C $75.72VOL 664.0K

RES: $99.08SUP: $71.48SMA50: $77.54SMA200: $79.56

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CBT Butterfly Map → + Track CBT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

1.6%/yr Implied 5Y Growth

vs. -7.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CBT)

Materials Rank #20 of 270 ⚔️ AVNT vs CBT Full Matrix →

1. Head-to-Head Materials Peer Comparison (CBT vs. AVNT, VVV, PRM, WDFC)

Industry: Major Chemicals (67 Tracked Issuers)

Across 270 tracked Materials securities in the Roarable RQD universe, Cabot Corporation (CBT) ranks #20 by composite RQD confidence (65/100, grade C) and #84 by equity capitalization ($3.84B). Within this direct 5-issuer industry benchmark cohort, CBT leads on earnings valuation at 11.5x trailing P/E, while WDFC leads on capital efficiency and profitability with 27.2% ROIC and 55.1% gross margin. WDFC currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with CBT at 65/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CBT ACTIVE Cabot Corporation	C	65/100	11.5x	25.3%	22.3%	+1.73%	$3.84B	Benchmark Subject
AVNT Avient Corporation	C+	69/100	48.0x	31.2%	3.7%	+1.42%	$3.93B	/avnt-vs-cbt →
VVV Valvoline Inc.	D	45/100	19.6x	38.5%	16.5%	+6.44%	$4.12B	/vvv-vs-cbt →
PRM Perimeter Solutions SA	D-	43/100	—	57.5%	-10.8%	0.00%	$4.59B	/prm-vs-cbt →
WDFC WD-40 Company	B	73/100	32.3x	55.1%	27.2%	+3.27%	$2.95B	/wdfc-vs-cbt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0000016040 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Cabot Corporation (CBT) reported GAAP revenue of $3.71B (-7.0% vs. FY2024 revenue of $3.99B , and -5.5% cumulative change since FY2023) , GAAP net income of $331.0M, operating cash flow of $665.0M, and free cash flow of $391.0M (-13.3% YoY). On the balance sheet, CBT closed FY2025 with $3.76B in total assets against $854.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$3.71B	$331.0M	$665.0M	$391.0M	$3.76B	$854.0M
FY2024 (FY)	2024-09-30	$3.99B	$380.0M	$692.0M	$451.0M	$3.64B	$1.09B
FY2023 (FY)	2023-09-30	$3.93B	$445.0M	$595.0M	$595.0M	—	—

3. CBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CBT compare to AVNT and VVV in the Materials sector?

What are the biggest fundamental strengths and SEC risk factors for CBT?

Where is CBT trading relative to its 50-day, 200-day, and 52-week technical levels?

CBT last traded at $75.72 (+1.73% on volume of 617,166 shares), positioning the stock -2.35% below its 50-day simple moving average ($77.54) and -4.83% below its 200-day simple moving average ($79.56). Across its 52-week range of $58.33 to $94.53, CBT sits at the 48.0% percentile with a 14-day RSI of 44.4 (NEUTRAL RANGE) and an implied next-earnings move of ±4.0% ($72.69 to $78.75).

Direct Sub-Reports: CBT RQD Cockpit CBT 12M Forecast CBT Earnings & Move CBT Dividends & DRIP CBT Insiders & 13F CBT Whale Options CBT Profit Sankey CBT News & Why

ROARABLE RATING BRIEF • RQD 65/100 (C) ✓ SEC XBRL & RQD VERIFIED

CBT — Cabot Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cabot Corporation (CBT) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $75.72 (+1.73% 1D, market capitalization $3.84B).

Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 22.3%, gross margin of 25.3%, operating margin of 16.7%, and free cash flow yield of 10.25%.
Whale 13F & Options Flow (7/20) + Insider Conviction (18/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (15/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 7/9, and Debt/Equity of 0.54x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cabot Corporation is a NYSE-listed issuer in the Materials sector and Major Chemicals industry. It reports annual revenue in the $3.7B–$4.0B range across the three periods shown.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Cabot Corporation (CBT) reported $3.71B in annual revenue (up from $3.99B in FY2024, -7.0% YoY) and $331.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.93B revenue, $445.0M net income) through FY2025, CBT scaled operating cash flow to $665.0M and free cash flow to $391.0M, backed by $3.76B in total assets against $854.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 65/100): Strong cash generator (25.3% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $58.33 – $94.53 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 11.5x trailing P/E and 5.2x EV/EBITDA against 16.7% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Major Chemicals (Materials), CBT carries a macro regime beta of 1.00 and gross margin of 25.3%.

Key Question #1: Can CBT sustain or expand its 16.7% operating margin and 22.3% ROIC against Major Chemicals peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $3.71B and free cash flow of $391.0M, how will capital allocation balance growth reinvestment against $854.0M in total debt?
Key Question #3: How sensitive is CBT's 10.7x forward P/E multiple to Materials capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CBT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cabot Corporation (CBT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CBT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Is Cabot (CBT) Stock Outpacing Its Basic Materials Peers This Year?

Yahoo Finance report covering Cabot Corporation (CBT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Here's Why You Should Add Cabot Stock to Your Portfolio Now

TradingView report covering Cabot Corporation (CBT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Is Cabot (CBT) Outperforming Other Basic Materials Stocks This Year?

Yahoo Finance report covering Cabot Corporation (CBT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Cabot Corporation (NYSE:CBT) Stock Has Consensus Price Target of $87.80

MarketBeat report covering Cabot Corporation (CBT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Interim CFO Steven J. Delahunt reports 5,399 directly held shares in Cabot (CBT) as of October 1.

Stock Titan report covering Cabot Corporation (CBT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Cabot Corporation Estimates – NYSE:CBT

TradingView report covering Cabot Corporation (CBT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Are Investors Undervaluing Cabot (CBT) Right Now?

Yahoo Finance report covering Cabot Corporation (CBT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Cabot Corporation (CBT) Slips to $73.79 as Shares Test Lower End of Recent Range - Swing Trade Setups

https://www.siam.in/ report covering Cabot Corporation (CBT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CBT Bull vs. Bear Conversation Board — What's Your Call at $75.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CBT 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $94.53 (+27.0%)

📌 Pinned Debate

Strong cash engine with ROIC of 22.3% and FCF yield of 10.25%, backed by an Insider Conviction pillar score of 18 of 20.

Strong cash engine with ROIC of 22.3% and FCF yield of 10.25%, backed by an Insider Conviction pillar score of 18 of 20.. When you look under the hood at CBT, Fundamental Cash Engine is 16/20 with 25.3% gross margins and 22.3% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $94.53. My 12M target is $94.53.

RetailWhale_TX 🐂 BULL

Both sides have a point here — CBT's 15/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $63.27 (-15.0%)

Spot @ $74.43

Macro Regime Fit scores only 9 of 20 with Beta of 1.0, while Whale 13F Flow scores just 6 of 20 and revenue has declined across the rep

Macro Regime Fit scores only 9 of 20 with Beta of 1.0, while Whale 13F Flow scores just 6 of 20 and revenue has declined across the reported periods.. Look at the math on CBT: paying 11.5x trailing P/E for 22.3% ROIC and 16.7% operating margins leaves zero margin of safety if Major Chemicals demand softens. I'd wait for a retest of $65.50 before getting long.